{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:06:38Z","timestamp":1784307998677,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bulcan.2026.02.009","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T20:11:46Z","timestamp":1778098306000},"page":"836-843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lymphome c\u00e9r\u00e9bral primitif\u00a0: exp\u00e9rience de treize ans d\u2019un service d\u2019h\u00e9matologie et oncologie p\u00e9diatrique \u00e0 Casablanca"],"prefix":"10.1016","volume":"113","author":[{"given":"Amine","family":"Benmoussa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Cheikhna Nane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Chakroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisrine","family":"Khoubila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham","family":"Cherkaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Lamchahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Rachid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdellah","family":"Madani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Qachouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bulcan.2026.02.009_bib0195","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/neuonc\/noab020","article-title":"Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"23","author":"Barajas","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.009_bib0200","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13045-022-01356-7","article-title":"Evidence-based expert consensus on the management of primary central nervous system lymphoma in China","volume":"15","author":"Chen","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2026.02.009_bib0205","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/nox187","article-title":"The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4\u00a0decades","volume":"20","author":"Mendez","year":"2018","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.02.009_bib0210","first-page":"352","article-title":"Challenges and opportunities in primary CNS lymphoma: a systematic review","volume":"122","author":"Kerbauy","year":"2017","journal-title":"Radiat Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.009_bib0215","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1158\/1078-0432.CCR-10-1161","article-title":"Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"17","author":"Abla","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"35","key":"10.1016\/j.bulcan.2026.02.009_bib0220","doi-asserted-by":"crossref","first-page":"e21844","DOI":"10.1097\/MD.0000000000021844","article-title":"Primary central nervous system lymphoma after heart transplantation: a case report and literature review","volume":"99","author":"Zhu","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.bulcan.2026.02.009_bib0225","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/neuonc\/noy192","article-title":"Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma","volume":"21","author":"Grommes","year":"2019","journal-title":"Neuro Oncol"},{"issue":"25","key":"10.1016\/j.bulcan.2026.02.009_bib0230","first-page":"419","article-title":"The diagnosis and treatment of primary CNS lymphoma","volume":"115","author":"Von Baumgarten","year":"2018","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"10.1016\/j.bulcan.2026.02.009_bib0235","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/00207454.2018.1523159","article-title":"Primary central nervous system lymphoma with no enhancemen initially and no significant progression over a long term: a case report and review of the literature","volume":"129","author":"Hu","year":"2019","journal-title":"Int J Neurosci"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.009_bib0240","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.bulcan.2026.02.009_bib0245","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36\u00a0cancers in 185\u00a0countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.bulcan.2026.02.009_bib0250","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3892\/ijo.2021.5180","article-title":"Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (review)","volume":"58","author":"Liu","year":"2021","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bulcan.2026.02.009_bib0255","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20130684","article-title":"Multimodality imaging of primary CNS lymphoma in immunocompetent patients","volume":"87","author":"Partovi","year":"2014","journal-title":"Br J Radiol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.02.009_bib0260","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.14073","article-title":"Trends in primary central nervous system lymphoma incidence and survival in the U.S","volume":"174","author":"Shiels","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2026.02.009_bib0265","doi-asserted-by":"crossref","first-page":"817043","DOI":"10.3389\/fonc.2022.817043","article-title":"Epidemiologic characteristics, prognostic factors, and treatment outcomes in primary central nervous system lymphoma: a SEER based study","volume":"12","author":"Tang","year":"2022","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2026.02.009_bib0270","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41408-021-00523-2","article-title":"Sequential CD19\/22\u00a0CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma","volume":"11","author":"Wu","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.bulcan.2026.02.009_bib0275","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10072-018-3669-7","article-title":"Imaging features (CT, MRI, MRS, and PET\/CT) of primary central nervous system lymphoma in immunocompetent patients","volume":"40","author":"Cheng","year":"2019","journal-title":"Neurol Sci"},{"key":"10.1016\/j.bulcan.2026.02.009_bib0280","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/aol-20-50","article-title":"Primary central nervous system lymphoma: epidemiology and clinical presentation","volume":"5","author":"Song","year":"2021","journal-title":"Ann Lymphoma"},{"issue":"3","key":"10.1016\/j.bulcan.2026.02.009_bib0285","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/PPO.0000000000000449","article-title":"Central nervous system lymphoma: approach to diagnosis and treatment","volume":"26","author":"Correia","year":"2020","journal-title":"Cancer J"},{"issue":"Suppl 5","key":"10.1016\/j.bulcan.2026.02.009_bib0290","first-page":"S51","article-title":"Review of Radiologic considerations in an immunocompetent patient with primary central nervous system lymphoma","volume":"36","author":"Miller","year":"2019","journal-title":"Fed Pract"},{"issue":"4","key":"10.1016\/j.bulcan.2026.02.009_bib0295","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.rxeng.2018.04.003","article-title":"Primary central nervous system lymphoma in immunocompetent patients: spectrum of findings and differential characteristics","volume":"60","author":"Gomez Rosello","year":"2018","journal-title":"Radiologia (Engl Ed)"},{"issue":"3","key":"10.1016\/j.bulcan.2026.02.009_bib0300","first-page":"1","article-title":"Primary central nervous system lymphom","volume":"XXIV","author":"Birzu","year":"2020","journal-title":"Lett Neurol"},{"issue":"5","key":"10.1016\/j.bulcan.2026.02.009_bib0305","first-page":"1","article-title":"Primary CNS lymphoma in India: a 17-year experience from the All India Institute of Medical Sciences","author":"Patekar","year":"2019","journal-title":"J Glob Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2026.02.009_bib0310","first-page":"415","article-title":"Diagnosis of primary central nervous system lymphoma: a systematic review of the utility of CSF screening and the role of early brain biopsy","volume":"6","author":"Morell","year":"2019","journal-title":"Neurooncol Pract"},{"issue":"3","key":"10.1016\/j.bulcan.2026.02.009_bib0315","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/PPO.0000000000000449","article-title":"Central nervous system lymphoma: approach to diagnosis and treatment","volume":"26","author":"Correia","year":"2020","journal-title":"Cancer J"},{"issue":"19","key":"10.1016\/j.bulcan.2026.02.009_bib0320","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","article-title":"Recurrent mutations of MYD88\u00a0and TBL1XR1\u00a0in primary central nervous system lymphomas","volume":"18","author":"Aguilar","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bulcan.2026.02.009_bib0325","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.bjc.6605559","article-title":"Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20\u00a0trial","volume":"102","author":"Joerger","year":"2010","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2026.02.009_bib0330","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.tranon.2018.11.011","article-title":"Primary central nervous system lymphoma: molecular pathogenesis and advances in treatment","volume":"12","author":"Cai","year":"2019","journal-title":"Transl Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.009_bib0335","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11060-011-0649-7","article-title":"Prophylactic intrathecal chemotherapy in primary CNS lymphoma","volume":"106","author":"Sierra del Rio","year":"2012","journal-title":"J Neurooncol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.02.009_bib0340","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1212\/WNL.58.10.1513","article-title":"A multicenter study of treatment of primary CNS lymphoma","volume":"58","author":"Ferreri","year":"2002","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.009_bib0345","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11060-010-0497-x","article-title":"Primary CNS lymphoma in patients younger than 60: can wholebrain radiotherapy be deferred?","volume":"104","author":"Omuro","year":"2011","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.bulcan.2026.02.009_bib0350","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2141.2012.09208.x","article-title":"Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis","volume":"158","author":"Prica","year":"2012","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.bulcan.2026.02.009_bib0355","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","article-title":"High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma","volume":"24","author":"Illerhaus","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.009_bib0360","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3324\/haematol.11771","article-title":"High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system","volume":"93","author":"Illerhaus","year":"2008","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.bulcan.2026.02.009_bib0365","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/annonc\/mds059","article-title":"Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study","volume":"23","author":"Kasenda","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.009_bib0370","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-006-9165-6","article-title":"Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors","volume":"80","author":"Jahnke","year":"2006","journal-title":"J Neurooncol"},{"issue":"9","key":"10.1016\/j.bulcan.2026.02.009_bib0375","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/neuonc\/now033","article-title":"Primary CNS lymphoma at first relapse\/progression: characteristics, management, and outcome of 256\u00a0patients from the French LOC network","volume":"18","author":"Langner-Lemercier","year":"2016","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2026.02.009_bib0380","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/leu.2017.128","article-title":"Improved survival in primary central nervous system lymphoma up to age 70\u00a0only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989\u20132015","volume":"31","author":"Van der Meulen","year":"2017","journal-title":"Leukemia"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126001773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126001773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:30:23Z","timestamp":1784305823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126001773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0007455126001773"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.02.009","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphome c\u00e9r\u00e9bral primitif\u00a0: exp\u00e9rience de treize ans d\u2019un service d\u2019h\u00e9matologie et oncologie p\u00e9diatrique \u00e0 Casablanca","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}